Why the study?
Does oral pretreatment with mioflazine improve functional recovery in dogs subjected to global myocardial ischaemia?
Does oral pretreatment with mioflazine improve functional recovery in dogs subjected to global myocardial ischaemia?
Mioflazine pretreatment demonstrates strong cardioprotective effects, improving functional and biochemical recovery in a canine model of severe global myocardial ischemia.
Hypothesis-generating for mioflazine cardioprotection in ischemia; prospective human trials needed before clinical adoption.
The cardioprotective effects of mioflazine, a recently developed cardiovascular drug, were investigated in 41 anaesthetised open chest Beagle dogs subjected to 1 h normothermic global myocardial ischaemia. The severity of the model is evidenced by the finding that only one out of 20 control dogs could be weaned from extracorporeal bypass. Oral pretreatment with mioflazine (2.5 mg X kg-1) resulted in complete functional recovery in 17 out of 20 animals. Biochemical analysis of left ventricular biopsies taken before, during and after aortic cross clamping showed a preservation of purines and a better recovery of ATP, ATP/ADP X Pi ratio and energy charge (p less than 0.05) in the pretreated animals. Morphological and cytochemical assessment of the myocardium demonstrated that the ultrastructure of the sarcolemma and its calcium binding capacity is remarkably well preserved in the drug treated animals. These results indicate a strong cardioprotective effect of mioflazine. The biochemical, cytochemical and ultrastructural findings suggest an interaction of the drug with the sarcolemma.
No takes yet. Share an insight, caveat, or question.
Flameng et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: